Ikena Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(68,166) | $(68,765) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation | 1,020 | 751 |
| Amortization of marketable securities | (2,023) | 50 |
| Stock-based compensation expense | 7,632 | 7,525 |
| Non-cash operating lease expense | 1,714 | 1,283 |
| Loss on disposal of property and equipment | 5 | 173 |
| Impairment of right of use asset | 1,744 | — |
| Net realized loss on marketable securities | — | 12 |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | 1,835 | 1,236 |
| Accounts payable | (2,870) | (291) |
| Accrued expenses and other current liabilities | (7,660) | 2,230 |
| Lease liability | (2,087) | (1,292) |
| Deferred revenue | (9,160) | (15,618) |
| Deposits and other assets | (1,824) | (1,403) |
| Other long-term liabilities | 97 | — |
| Net cash flows used in operating activities | (79,743) | (74,109) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (414) | (1,431) |
| Purchases of marketable securities | (90,052) | (216,338) |
| Sales and maturities of marketable securities | 154,610 | 118,485 |
| Net cash flows provided by (used in) investing activities | 64,144 | (99,284) |
| Cash flows from financing activities | ||
| Cash and cash equivalents acquired in connection with the acquisition of Pionyr, net of issuance costs paid | 40,030 | — |
| Cash consideration paid in connection with the acquisition of Pionyr | (944) | — |
| Proceeds from issuance of common stock for underwritten registered offering, net of offering costs | 37,421 | — |
| Repurchase of common stock | (663) | — |
| Proceeds from exercise of stock options | 136 | 1,095 |
| Net cash flows provided by financing activities | 75,980 | 1,095 |
| Net increase (decrease) in cash and cash equivalents | 60,381 | (172,298) |
| Cash, cash equivalents and restricted cash, beginning of year | 60,791 | 233,089 |
| Cash, cash equivalents and restricted cash, end of year | $121,172 | $60,791 |
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | ||
| Cash and cash equivalents | $119,894 | $59,919 |
| Restricted cash included in other assets | 1,278 | 872 |
| Cash, cash equivalents and restricted cash, end of year | $121,172 | $60,791 |
| Supplemental disclosure of non-cash activities | ||
| Right-of-use asset recognized upon assumption of San Francisco, CA lease from Pionyr | $3,889 | $— |
| Purchases of property and equipment in accounts payable and accrued expenses | $— | $259 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.